General
Osimertinib tops standard first-line TKI therapy for advanced NSCLC | News for Doctor, Nurse, Pharmacist | Oncology | MIMS Malaysia
 

Osimertinib tops standard first-line TKI therapy for advanced NSCLC | News for Doctor, Nurse, Pharmacist | Oncology | MIMS Malaysia

Shared by:

 
Osimertinib tops standard first-line TKI therapy for advanced NSCLC in European Society for Medical Oncology (ESMO) Congress 2017 | MIMS Malaysia
 
specialty.mims.com
 
21 Sep 2017 - General
 
Thx Shunjie for your respon and I happy to know you, I agree with you about developing new preparat for lung cancer ecspesialy in NSCLC due the target therapy, I agree that it has beneficial to patient in lungcancer in term in progression and the quality of life, in order to help the patient life more longer with undergo life with the good aktifities..and thx for Madhubabu for respon and nice to know you,this preparat isn't available in my country, the nearest country we can get it is in Sin...
 (Total 111 words)